Team:USTC CHINA/Project/Background
From 2013.igem.org
(Difference between revisions)
Line 63: | Line 63: | ||
<h1>Background</h1> | <h1>Background</h1> | ||
<h2>2013, We Redefined Vaccine<h2> | <h2>2013, We Redefined Vaccine<h2> | ||
- | <p align="justify">In our world, billions of people are suffering from contagions | + | <p align="justify">In our world, billions of people are suffering from contagions while only parts of contagions can be effectively prevented by existing vaccines. The disadvantages of traditional vaccines, like being produced and purified with strict requirements on temperature, have limited their application, especially in developing countries.<p> |
<h3>the Comparison of Different Vaccine Delivery Ways<h3> | <h3>the Comparison of Different Vaccine Delivery Ways<h3> | ||
<img src="https://static.igem.org/mediawiki/2013/d/d7/USTC_CHINA_Traditional_needles.png" width="600" height="375" /> | <img src="https://static.igem.org/mediawiki/2013/d/d7/USTC_CHINA_Traditional_needles.png" width="600" height="375" /> | ||
<img src="https://static.igem.org/mediawiki/2013/3/31/USTC_CHINA_advantages_T-vaccine.png" width="600" height="600" /> | <img src="https://static.igem.org/mediawiki/2013/3/31/USTC_CHINA_advantages_T-vaccine.png" width="600" height="600" /> | ||
- | <p align="justify"> | + | <p align="justify">One solution to the problems is making change in drug delivery and create an in situ expression system based on synthetic biology.<p> |
<h2>Design of Project<h2> | <h2>Design of Project<h2> | ||
- | <p align="justify"> This year, our project focused on a revolutionary vaccine delivery. We chose bacillus subtilis as chassis to establish a transdermal vaccine fresh secreting band-aid which consists of four engineering b.subtilis, each of them carries a gene circuit independently. By using an excellent transdermal peptide TD1, three of them could express a | + | <p align="justify">This year, our project focused on a revolutionary vaccine delivery. We chose bacillus subtilis as chassis to establish a transdermal vaccine fresh secreting band-aid which consists of four engineering b.subtilis, each of them carries a gene circuit independently. By using an excellent transdermal peptide TD1, three of them could express a series of fusion proteins(antigen, 2 kinds of adjuvants), which could penetrate the skin and work as traditional vaccine molecules. The fourth type is our "reporter" , which could notify users whether the band-aid works well and when they could stick or tear off the patch. Moreover, we designed a reliable suicide system in Bacillus subtilis for the very first time in iGEM. Innovative and incredible, we plan to create a world without needles.<p> |
- | <h2> | + | <h2>How do we realize T-vaccine<h2> |
<h3>1. Transdermal Peptide 1:<h3> | <h3>1. Transdermal Peptide 1:<h3> | ||
- | <p align="justify">When this idea first stroke us, it seemed | + | <p align="justify">When this idea first stroke us, it seemed that our dream is too naive and unpractical. |
+ | The most obvious problem is to make antigen get across the skin barrier, and we looked up various transdermal methods, like Iontophoresis, Sonophoresis, Microneedles,all of which require special equipment and can harm skin. Our idea remained unrealistic until we find Transdermal peptide 1.<p> | ||
<p align="justify">TD-1 is an eleven amino acid peptide, which can greatly facilitate macromolecule transdermal delivery through intact skin. This was first discovered by professor Wen Longping in our university and the results were published on Nature biotechnology.<p> | <p align="justify">TD-1 is an eleven amino acid peptide, which can greatly facilitate macromolecule transdermal delivery through intact skin. This was first discovered by professor Wen Longping in our university and the results were published on Nature biotechnology.<p> | ||
TD1 Sequence<br> | TD1 Sequence<br> | ||
Line 80: | Line 81: | ||
<img src="https://static.igem.org/mediawiki/2013/a/a7/Nature.png" width="580" height="400" /> | <img src="https://static.igem.org/mediawiki/2013/a/a7/Nature.png" width="580" height="400" /> | ||
<h3>2. the Principle of TD1:<h3> | <h3>2. the Principle of TD1:<h3> | ||
- | <p align="justify">TD1 can greatly assist macromolecule transdermal delivery | + | <p align="justify">TD1 can greatly assist macromolecule transdermal delivery across intact skin. It creates a transient opening in the skin barrier, enabling macromolecule to reach systemic circulation.<p> |
<img src="https://static.igem.org/mediawiki/2013/8/81/%E4%B8%9D%E7%8A%B6%E5%99%AC%E8%8F%8C%E4%BD%93.png" width="580" height="500" /> | <img src="https://static.igem.org/mediawiki/2013/8/81/%E4%B8%9D%E7%8A%B6%E5%99%AC%E8%8F%8C%E4%BD%93.png" width="580" height="500" /> | ||
<p><strong>Phage Library Screening</strong></p><br> | <p><strong>Phage Library Screening</strong></p><br> | ||
<img src="https://static.igem.org/mediawiki/2013/5/5e/EGFP.png" width="580" height="350" /> | <img src="https://static.igem.org/mediawiki/2013/5/5e/EGFP.png" width="580" height="350" /> | ||
- | <p>With | + | <p>With eGFP, we could visualize whether the TD1-eGFP has transmitted across the skin. Besides, we can easily see the path of TD1-eGFP.</p><br> |
Revision as of 04:25, 19 October 2013